|
1. BIOLOGIE
|
|
|
|
4.11 DÉP., DIAG. & PRONO. - OVAIRE
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
|
|
|
|
5.12.6 IMMUNOTHÉRAPIES - AMM
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
The top 10 pharma R&D budgets in 2019 [Fierce Pharma]
|
|
|
|
|
|
Looking through the main programs across all the top 10 companies, it’s immediately clear oncology is still the biggest therapeutic category when it comes to spending. Cancer R&D has traditionally been expensive, but the FDA’s willingness to approve treatments on more limited data is cutting costs and offering a quicker path to market.
|
|
|
|
|
|
|
6.15 LUTTE CONTRE LES CANCERS - COVID-19
|
|
|
|
Global oncology pharmacists face restricted access to essential PPE items, UCI study finds [UCI]
|
|
|
|
|
|
In the Journal of Oncology Pharmacy Practice, Alexandre Chan, department chair and professor clinical pharmacy practice, and Canadian and Australian colleagues of the International Society of Oncology Pharmacy Practitioners surveyed 42 pharmacy practice groups in 28 countries and regions (in both developed and developing countries) to determine pain points that this global pandemic has created for oncology pharmacy practitioners.
|
|
|
|
|
|